Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Universal 3D printer bioink for Type 1 diabetes cell therapy

Project description

3D bioprinting for diabetes treatment

People with type 1 diabetes (T1DM) cannot produce insulin because their immune system destroys the cells that make it. Insulin injections help manage blood sugar levels, but do not replicate the body’s natural regulation process. Scientists have been working on 3D microspheres that hold insulin-producing cells for transplants or drug testing. However, current methods for making these microspheres are slow, inconsistent, and often rely on materials that do not fully support cell growth. The ERC-funded UNIINK project is developing a new 3D bioprinting technique to create better microspheres. Using a material that mimics the body’s natural environment and strengthening it with tannic acid, UNIINK enhances nutrient delivery and cell survival. This breakthrough could bring new hope to T1DM patients.

Objective

Type 1 Diabetes (T1DM) results from autoimmune destruction of pancreatic insulin-producing -cells. Nowadays, insulin injections remain the leading therapeutic option. However, injection treatment fails to emulate the highly dynamic insulin release that -cells provide. During the last years, 3D cell-laden microspheres have been proposed as a major platform for bioengineering insulin-secreting constructs for tissue graft implantation and a model for in vitro drug screening platforms.
Current microsphere fabrication technologies have several drawbacks: the need for an oil phase containing surfactants, diameter inconsistency of the microspheres, and high time-consuming processes, among others. These technologies have widely used alginate for its rapid gelation, high processability, and low cost. However, its low biocompatible properties do not provide effective cell attachment. To overcome these limitations, Uniink proposes a high-throughput 3D bioprinting methodology that employs an ECM-like microenvironment for effective cell-laden microsphere production. Crosslinking the resulting microspheres with tannic acid (TA) prevents collagenase degradation and enhances spherical structural consistency while allowing the diffusion of nutrients and oxygen. In addition, the approach allows customization of microsphere diameter with extremely low variability. In conclusion, we will develop in Uniink a novel bio-printing procedure to fabricate large amounts of reproducible microspheres capable of secreting insulin in response to extracellular glucose stimuli. We expect that Uniink will represent a valid alternative to islet transplantation in T1DM patients, thus bringing cell therapy closer to the application in humans.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2022-POC2

See all projects funded under this call

Host institution

FUNDACIO INSTITUT DE BIOENGINYERIA DE CATALUNYA
Net EU contribution
€ 150 000,00
Address
CARRER BALDIRI REIXAC PLANTA 2A 10-12
08028 Barcelona
Spain
Region
Este Cataluña Barcelona
Activity type
Research Organisations
Links
Total cost
No data

Beneficiaries (1)